Bibliography
- Ling W , CasadonteP, BigelowGet al. Buprenorphine implants for treatment of opioid dependence: a randomized controlled trial. JAMA 304, 1612–1614 (2010).
Websites
- Pfizer to acquire King Pharmaceuticals, Inc. http://pfizer.mediaroom.com/index.php?s=5149&item=14615
- Embeda® (morphine sulfate and naltrexone) extended-release capsules. www.embeda.com
- Bristol-Myers Squibb completes acquisition of ZymoGenetics, Inc. www.bms.com/news/press_releases/pages/default.aspx
- Recothrom® is the first human thrombin approved by the US FDA that is produced via recombinant DNA technology. www.recothrom.com/about_recothrom/default.aspx
- ZymoGenetics reports favorable survival data from IL-21 Phase IIa clinical trial in melanoma. www.fiercebiotech.com/press-releases/zymogenetics-reports-favorable-survival-data-il-21-phase-2a-clinical-trial-melanoma-0
- ImmunoGen, Inc. announces collaboration for rights to use ImmunoGen‘s TAP technology. http://phx.corporate-ir.net/phoenix.zhtml?c=97573&p=irol-newsArticle&ID=1480878&highlight=
- Lundbeck and Genmab enter into a research collaboration. http://ie.lundbeck.com/investor/releases/ReleaseDetails/Release_1451485_EN.asp
- Fate Therapeutics announces collaboration with BD to develop and commercialize induced pluripotent stem cell technology. www.fatetherapeutics.com/pdf/20101014_PressRelease.pdf
- Stem cell reprogramming technology iPSC by Fate Therapeutics gets US patent. www.dancewithshadows.com/pillscribe/stem-cell-reprogramming-technology-ipsc-by-fate-therapeutics-gets-us-patent/
- US FDA approves first oral drug to reduce MS lapses. www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm226755.htm
- Novartis gains US FDA approval for Gilenya™, a novel first-line multiple sclerosis treatment shown to significantly reduce relapses and delay disability progression. www.novartis.com/newsroom/media-releases/en/2010/1445917.shtml
- Alkermes announces US FDA approval of Vivitrol® for prevention of relapse to opioid dependence. http://phx.corporate-ir.net/phoenix.zhtml?c=92211&p=irol-newsArticle&ID=1481879&highlight=
- Vivitrol® (naltrexone for extended-release injectable suspension: dosage and administration. www.vivitrol.com/hcp/Vivitrol_Info/dosing_administration.aspx
- European Medicines Agency recommends suspension of Avandia®, Avandamet® and Avaglim®. Link
- US FDA significantly restricts access to the diabetes drug Avandia®. www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/ucm226956.htm
- GSK regulatory update on Avandia® following EMA and FDA reviews. www.gsk.com/media/pressreleases/2010/2010_pressrelease_10103.htm
- Novartis drug SOM230 is first medical therapy to show efficacy in a Phase III trial in Cushing‘s disease, a debilitating hormonal disorder. www.novartis.com/newsroom/media-releases/en/2010/1445885.shtml
- The PASPORT research program – a global clinical research program to advance patient care. www.pasporttrials.com/index.jsp
- Abiraterone acetate significantly improved overall survival rates for patients with metastatic advanced prostate cancer. Link
- Abbott reports psoriasis Phase III results of its investigational IL-12/23 inhibitor briakinumab (ABT-874). www.abbott.com/global/url/pressRelease/en_US/60.5:5/Press_Release_0909.htm
- Titan Pharmaceuticals announces Journal of the American Medical Association publication of Phase III Probuphine™ data. www.titanpharm.com/101012-press-rel-jama.php
- Essentialis strengthens patent protection of its novel ATP-sensitive potassium channel opener portfolio. Link
- Syndax Pharmaceuticals announces issuance of UK patent for entinostat. www.syndax.com/assets/101307%20Syndax%20UK%20Patent%20Release%20final.pdf